A federal judge decided to unseal confidential materials about the top-selling drug Zyprexa, citing “the health of hundreds of thousands of people” and “fundamental questions” about the way drugs are approved for new uses. Class-action suits claim that the pharmaceutical company, Eli Lilly, hid the side effects of the drug and marketed in for unapproved uses. Patients claim to Zyprexa caused excessive weight gain and diabeties. The judge stated that Lilly’s legitimate interest in confidentiality does not outweigh the public interest in disclosure at this stage. Drug and Pharmacy Errors are of great public concern and pharmaceutical companies are required to inform consumers of all possible side effects. To read the full story, click here.